# Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

> **NCT03787680** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** AZD6738

## Key facts

- **NCT ID:** NCT03787680
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-31
- **Primary completion:** 2023-01-26
- **Final completion:** 2028-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787680, "Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03787680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*